Skip to content
Peptigraph home
Shop Peptides50% off*

Ipamorelin Results: What Studies Measured and When

What published studies measured for Ipamorelin, when those outcomes were measured, and what is still unproven.

Medical review pendingGHRP (ghrelin receptor agonist)Updated

What studies measured

Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.

Ipamorelin outcomes in published studies
OutcomeResultStudy typeSource
Time to first tolerated mealMedian time to first tolerated meal was 25.3 h with ipamorelin and 32.6 h with placebo, a difference that was not statistically significant.Human RCTn = 117International journal of colorectal disease 2014, PMID 25331030
Overall efficacyNo significant difference from placebo in the key or secondary efficacy analyses.Human RCTn = 117International journal of colorectal disease 2014, PMID 25331030
GH releaseA single episode of GH release peaked at 0.67 hours and fell to negligible levels at all doses.Human RCTPharmaceutical research 1999, PMID 10496658
Regulatory status and evidence for physique claimsThe review notes no regulatory approval for physique- or performance-related indications of these peptides, including ipamorelin.ReviewFrontiers in endocrinology 2026, PMID 42395176
Cisplatin-induced weight lossIpamorelin did not change emesis but reduced cisplatin-induced weight loss by approximately 24% on the last day of the delayed phase (48-72 h).Animal · ferret (not a human result)Physiology & behavior 2024, PMID 39043357
Visceral and somatic pain behaviourIpamorelin reduced colonic hypersensitivity and paw allodynia in rats; the models are not joint or back pain models.Animal · rat (not a human result)Journal of experimental pharmacology 2020, PMID 32801950
Gastric emptyingAfter surgery 78% of the meal remained in the stomach in vehicle rats versus 52% with ipamorelin 0.014 umol/kg (44% in non-surgical controls).Animal · rat (not a human result)Journal of experimental pharmacology 2012, PMID 27186127
Food intake and weight gainRepeated dosing at 0.1 or 1 mg/kg increased fecal output, food intake and body weight gain in rats after surgery.Animal · rat (not a human result)The Journal of pharmacology and experimental therapeutics 2009, PMID 19289567
Muscle strength and bone formation under glucocorticoidAdding ipamorelin to glucocorticoid increased calf-muscle tetanic tension and raised periosteal bone formation four-fold versus glucocorticoid alone.Animal · rat (not a human result)Growth hormone & IGF research 2001, PMID 11735244
Body weight and bone mineral contentIpamorelin, another GHRP and GH all increased body weight and bone mineral content versus vehicle; BMC per body weight was unchanged.Animal · rat (not a human result)The Journal of endocrinology 2000, PMID 10828840
Bone growth and body weightLongitudinal bone growth rose dose-dependently from 42 microm/day (vehicle) to 44, 50 and 52 microm/day, with dose-dependent body weight gain.Animal · rat (not a human result)Growth hormone & IGF research 1999, PMID 10373343
Selectivity for GH releaseIpamorelin released GH with selectivity similar to GHRH in these preclinical models.Animal · rat and swine (plus rat pituitary cells in vitro) (not a human result)European journal of endocrinology 1998, PMID 9849822
ACTH and cortisolUnlike other GHRP agonists, ipamorelin did not raise ACTH or cortisol beyond GHRH-stimulated levels in swine.Animal · rat and swine (plus rat pituitary cells in vitro) (not a human result)European journal of endocrinology 1998, PMID 9849822
Clearance and nasal absorptionIntranasal bioavailability of ipamorelin in rats was approximately 20%.Animal · rat (not a human result)Xenobiotica; the fate of foreign compounds in biological systems 1998, PMID 9879640
  • Human evidence is limited to two studies: a phase 2 randomized trial in 117 bowel-resection patients (25331030) that found no significant benefit over placebo for time to first tolerated meal, and a pharmacokinetic/pharmacodynamic study in healthy male volunteers (10496658). No human trial of ipamorelin for the listed lifestyle goals has been published in PubMed as of 2 October 2026.
  • No human study found for: energy, sleep, joint pain, arthritis, rheumatoid arthritis, back pain, menopause or perimenopause, longevity, belly fat, blood pressure, cholesterol, heart health, bulking, cutting, or age-specific goals (men and women over 40 or 50).
  • Everything else is animal work (rat, swine, ferret) or pharmacology. The pain study (32801950) used visceral and paw hypersensitivity models, not joint or back pain. Body-weight and bone findings in rats do not show effects in people.
  • Ipamorelin is not an approved drug and has no FDA label. No stability study was found.
  • No named adverse events were found for ipamorelin in PubMed or ClinicalTrials.gov as of 2026-10-11 (query: ipamorelin AND adverse/side effect/safety/tolerability/toxicity/case report; 11 hits). The phase 2 postoperative-ileus trial (NCT00672074) reports only the overall rate of treatment-emergent adverse events (87.5% ipamorelin vs 94.8% placebo) and has no posted results table, so individual events cannot be named.

Typical timeline

When measurable changes appeared in studies of Ipamorelin: not reported in study abstracts (PubMed search, 11 Oct 2026).

Before-and-after photos

We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.

Human results

In the bowel-resection trial, one hundred seventeen patients were enrolled and 114 formed the safety and modified intent-to-treat populations.[1]

Volunteers given ipamorelin infusions showed GH release at every dose level, with half-maximal stimulation at 214 nmol/L.[2]

The trial authors note their proof-of-concept study was small and enrolled patients with a broad range of underlying conditions.[1]

Animal results with timepoints

Rats given ipamorelin had a longitudinal bone growth rate of 44, 50 and 52 microm/day against 42 microm/day for vehicle.[10]

In a rat study, ipamorelin raised total bone mineral content measured by DXA, but the ratio to body weight was unaffected.[9]

In rats after laparotomy, intravenous ipamorelin at 0.014 µmol/kg left 52% of a test meal in the stomach, compared with 44% in nonsurgical controls.[6]

Common questions

How long does Ipamorelin take to work?

The study abstracts we summarised for Ipamorelin do not report when outcomes were measured (PubMed search, 11 Oct 2026).

Do you show Ipamorelin before and after photos?

No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.

More on Ipamorelin

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  2. 2Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  3. 3The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  4. 4The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
  5. 5Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.Journal of experimental pharmacology · 2020PMID 32801950Accessed 2 Oct 2026
  6. 6Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.Journal of experimental pharmacology · 2012PMID 27186127Accessed 2 Oct 2026
  7. 7Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.The Journal of pharmacology and experimental therapeutics · 2009PMID 19289567Accessed 2 Oct 2026
  8. 8The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001PMID 11735244Accessed 2 Oct 2026
  9. 9The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.The Journal of endocrinology · 2000PMID 10828840Accessed 2 Oct 2026
  10. 10Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999PMID 10373343Accessed 2 Oct 2026
  11. 11Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
  12. 12Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.Xenobiotica; the fate of foreign compounds in biological systems · 1998PMID 9879640Accessed 2 Oct 2026
  13. 13PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026

Found an error? Report a correction.